IBOV 165,528.92 ▼ 1.42% IPC MEX 70,184.33 ▲ 0.58% MERVAL 2,848,945 — — USD/BRL5.49▼ 0.03% USD/MXN18.59▼ 1.32% USD/CLP980.56▲ 0.29% USD/COP3,237▲ 0.33% USD/PEN3.45▼ 0.44% USD/ARS1,551▼ 0.02% USD/UYU40.19▲ 3.30% USD/PYG5,936▲ 3.60% USD/BOB12.05▲ 2.28% USD/DOP60.50▲ 0.83% USD/CRC449.50▲ 2.08% USD/GTQ7.64▲ 3.13% USD/HNL26.88▲ 3.25% USD/NIO36.62▲ 2.78% USD/VES890.98▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.59▲ 2.40% USD/TTD6.69▲ 2.14% EUR/BRL6.17▲ 1.46% BRENT 109.58 ▼ 5.38% WTI 100.12 ▼ 1.61% IRON ORE 161.91 — — COPPER 6.65 ▲ 2.24% GOLD 4,073 ▲ 0.85% SILVER 54.49 ▲ 0.70% SOY 1,250 ▲ 0.70% CORN 450.25 ▼ 1.04% WHEAT 614.75 ▼ 0.20% COFFEE 294.35 ▼ 2.19% SUGAR 19.26 ▲ 0.84% ORANGE JUICE 143.20 ▲ 5.45% COTTON 77.90 ▼ 1.47% COCOA 5,581 ▲ 1.66% BEEF 230.73 ▲ 0.33% CATTLE 346.40 ▼ 1.00% LITHIUM 62.43 ▲ 1.89% PETR4 53.31 ▼ 1.06% VALE3 62.88 ▼ 2.33% ITUB4 41.42 ▼ 0.67% BBDC4 15.69 ▼ 1.63% ABEV3 15.40 ▲ 0.20% BBAS3 17.59 ▲ 0.69% B3SA3 15.27 ▲ 1.33% WEGE3 45.78 ▲ 2.81% PRIO3 69.21 ▼ 2.71% SUZB3 47.14 ▼ 0.55% RENT3 31.14 ▼ 1.67% AZZA3 16.72 ▲ 1.15% CSAN3 2.69 ▼ 2.89% RAIZ4 0.34 — 0.00% PCAR3 2.22 ▼ 3.48% GMAT3 3.74 ▲ 2.19% PSSA3 47.75 ▼ 0.89% CVCB3 0.98 — 0.00% POSI3 3.56 ▼ 0.84% SLCE3 16.97 ▼ 2.75% NATU3 5.68 ▼ 3.89% BRKM5 3.80 ▲ 19.50% RANI3 7.34 ▼ 0.54% CSNA3 4.76 ▼ 4.99% IBOV 165,528.92 ▼ 1.42% IPC MEX 70,184.33 ▲ 0.58% MERVAL 2,848,945 — — USD/BRL 5.34 ▼ 1.32% USD/MXN 18.69 ▲ 0.62% USD/CLP 983.47 ▼ 0.57% USD/COP 3,149 ▲ 3.06% USD/PEN 3.45 ▲ 0.17% USD/ARS 1,537 ▼ 0.28% USD/UYU 40.21 ▲ 3.57% USD/PYG 5,803 ▲ 3.78% USD/BOB 11.97 ▲ 4.93% USD/DOP 60.54 ▲ 1.83% USD/CRC 451.24 ▲ 2.13% USD/GTQ 7.64 ▲ 3.23% USD/HNL 26.87 ▲ 3.37% USD/NIO 36.62 ▲ 2.81% USD/VES 885.08 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 2.63% USD/TTD 6.71 ▲ 2.07% EUR/BRL 5.95 ▲ 7.53% BRENT 109.58 ▼ 5.38% WTI 100.12 ▼ 1.61% IRON ORE 161.91 — — COPPER 6.65 ▲ 2.24% GOLD 4,073 ▲ 0.85% SILVER 54.49 ▲ 0.70% SOY 1,250 ▲ 0.70% CORN 450.25 ▼ 1.04% WHEAT 614.75 ▼ 0.20% COFFEE 294.35 ▼ 2.19% SUGAR 19.26 ▲ 0.84% ORANGE JUICE 143.20 ▲ 5.45% COTTON 77.90 ▼ 1.47% COCOA 5,581 ▲ 1.66% BEEF 230.73 ▲ 0.33% CATTLE 346.40 ▼ 1.00% LITHIUM 62.43 ▲ 1.89% PETR4 53.31 ▼ 1.06% VALE3 62.88 ▼ 2.33% ITUB4 41.42 ▼ 0.67% BBDC4 15.69 ▼ 1.63% ABEV3 15.40 ▲ 0.20% BBAS3 17.59 ▲ 0.69% B3SA3 15.27 ▲ 1.33% WEGE3 45.78 ▲ 2.81% PRIO3 69.21 ▼ 2.71% SUZB3 47.14 ▼ 0.55% RENT3 31.14 ▼ 1.67% AZZA3 16.72 ▲ 1.15% CSAN3 2.69 ▼ 2.89% RAIZ4 0.34 — 0.00% PCAR3 2.22 ▼ 3.48% GMAT3 3.74 ▲ 2.19% PSSA3 47.75 ▼ 0.89% CVCB3 0.98 — 0.00% POSI3 3.56 ▼ 0.84% SLCE3 16.97 ▼ 2.75% NATU3 5.68 ▼ 3.89% BRKM5 3.80 ▲ 19.50% RANI3 7.34 ▼ 0.54% CSNA3 4.76 ▼ 4.99%
since 2009
Wednesday, November 4, 2026

Crypto Brazil

The Price of Coercion: Public Turns Against mRNA Technology

By · November 18, 2024 · 2 min read

The pharmaceutical industry’s aggressive promotion of mRNA vaccines during the COVID-19 pandemic has resulted in an unprecedented crisis of public trust. Recent data from a comprehensive WHO-affiliated study reveals the extent of this backlash, with implications far beyond the pandemic.

The numbers tell a stark story. Among 740,533 analyzed tweets, 69.5% expressed negative sentiments towards mRNA technology. Safety concerns dominated the discourse, with 362,850 tweets (66.9%) deeming mRNA vaccines unsafe. Trust in authorities plummeted, with 57.2% of discussions reflecting outright distrust.

While skepticism spans the globe, some regions show particularly strong resistance. Tanzania, Colombia, and Russia lead in negative sentiment, each showing rejection rates above 75%. Even in regions with historically high vaccine acceptance, confidence has eroded significantly.

Free daily brief — no card needed
Get every Brazil story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.
The Price of Coercion: Public Turns Against mRNA Technology
The Price of Coercion: Public Turns Against mRNA Technology.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

The damage extends beyond vaccines. A significant 13.9% of respondents reported decreased trust in science itself due to COVID-19 vaccine development. The pharmaceutical industry suffered even more, with 18.7% reporting diminished trust.

The Price of Coercion: Public Turns Against mRNA Technology

The consequences are already visible. Only 28% of U.S. adults have received updated COVID-19 vaccines, despite aggressive promotion. This represents a dramatic shift from 2021, when 69% of adults sought full vaccination.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Brazil denies rate-cap plan before Wednesday's vote”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

The mRNA therapeutics market, valued at $52.85 billion in 2023, faces uncertain growth prospects. While projections suggest expansion to $113.41 billion by 2028, widespread public rejection threatens these forecasts.

https://www.riotimesonline.com/brazil-news/modern-day-censorship/already-98-new-mrna-vaccines-against-flu-hiv-and-much-more-in-the-pipeline/

The rushed development and emergency authorization of mRNA vaccines created lasting suspicion. Public perception of these products as “experimental” persists, fueled by concerns about long-term effects and biological mechanisms. The industry’s lack of transparency and aggressive promotion tactics have only deepened this mistrust.

The pharmaceutical industry now faces a critical challenge. Future mRNA-based innovations, including promising cancer treatments, risk rejection due to this erosion of trust. The Texas GOP’s stance against mRNA technology exemplifies how public skepticism has transformed into political opposition.

This crisis serves as a cautionary tale about the consequences of forcing medical innovations without adequate public trust and transparency. The industry’s path forward requires a fundamental shift in approach, prioritizing transparency and genuine public engagement over forced adoption.

Download study here.

This article was drafted with automated assistance and reviewed before publication. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.